The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long term results of a randomized phase III study of nimotuzumab in combination with concurrent radiotherapy and cisplatin versus radiotherapy and cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck.
 
Vijay Maruti Patil
Research Funding - AstraZeneca (Inst); Eisai Germany (Inst); Intas (Inst); Johnson & Johnson/Janssen (Inst); NATCO Pharma (Inst); Novartis (Inst)
 
Vanita Noronha
Research Funding - AstraZeneca (Inst); Johnson & Johnson/Janssen (Inst); Merck (Inst); Nanobiotix (Inst); Novartis (Inst); Roche India (Inst)
Travel, Accommodations, Expenses - American Society of Clinical Oncology
 
Nandini Sharrel Menon
No Relationships to Disclose
 
Minit Jalan Shah
No Relationships to Disclose
 
Sarbani Laskar Ghosh
No Relationships to Disclose
 
Ashwini Budrukkar
No Relationships to Disclose
 
Monali Swain
No Relationships to Disclose
 
Arun Balaji
No Relationships to Disclose
 
Devendra Chaukar
No Relationships to Disclose
 
Prathamesh S Pai
No Relationships to Disclose
 
Pankaj Chaturvedi
No Relationships to Disclose
 
Kumar Prabhash
Research Funding - Alkem Laboratories (Inst); BDR Pharmaceutics (Inst); Biocon (Inst); Dr. Reddy's Laboratories (Inst); Fresenius Kabi (Inst); NATCO Pharma (Inst); Roche (Inst)